GlassScriptPhysician profile
Amy N Head
NPI 1386990356
$3,674.39
in general payments reported to CMS, 2019-2025
29 companies · $805 in 2025
The $805 reported for 2025 was more than what 83% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $496 · 2022: $613 · 2023: $766 · 2024: $995 · 2025: $805.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,565.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,565.29 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,098.75 | 2021-2025 | |
| Lilly USA, LLC | $252.26 | 2023-2025 | Mounjaro, Zepbound, Jardiance |
| Novo Nordisk INC | $248.00 | 2023-2025 | Ozempic, Wegovy, Rybelsus |
| Abbott Laboratories | $221.53 | 2021-2024 | Proclaim, Freestyle Libre 3 |
| Bayer Healthcare Pharmaceuticals INC. | $163.86 | 2021-2023 | |
| Abiomed | $149.39 | 2022 | |
| Phathom Pharmaceuticals, INC. | $149.08 | 2024 | Voquezna |
| Amgen INC. | $145.25 | 2023-2025 | Otezla, Repatha, Otezla |
| Mayne Pharma Commercial LLC | $124.74 | 2023 | |
| Genzyme Corporation | $120.58 | 2024 | |
| Axsome Therapeutics, INC. | $119.70 | 2025 | Auvelity |
| Pfizer INC. | $109.05 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $94.48 | 2022 | |
| Gilead Sciences, INC. | $92.99 | 2021 | |
| Evoke Pharma, INC. | $90.17 | 2022 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ultragenyx Pharmaceutical INC. | $88.20 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $80.22 | 2021-2023 | Jardiance |
| Exact Sciences Corporation | $60.07 | 2023-2025 | Cologuard Collection Kit |
| Tris Pharma INC | $37.04 | 2024-2025 | Dyanavel Xr |
| Eisai INC. | $35.50 | 2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $33.54 | 2022 | |
| Astellas Pharma US INC | $30.67 | 2021-2024 | Veozah |
| Medtronic, INC. | $28.03 | 2025 | Inpen Smart Insulin Delivery System |
| Xeris Pharmaceuticals, INC. | $23.87 | 2023 | Gvoke Hypopen |
| Idorsia Pharmaceuticals US INC | $18.73 | 2024 | Quviviq |
| Sanofi-Aventis U.S. LLC | $17.96 | 2021 | |
| Glaxosmithkline, LLC. | $16.10 | 2024 | Trelegy Ellipta, Arexvy |
| Jazz Pharmaceuticals INC. | $12.90 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $11.73 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amy Head listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.